Gastric cancer immunotherapy is still being explored

Share This Post

Gastric cancer immunotherapy is still an exciting research area, especially the pd-1 inhibitors pembrolizumab (Keytruda) and nivolumab (Nivolumab, Opdivo).

In the Phase III ONO-4538-12 trial, nivolumab third-line or follow-up treatment reduced the risk of death in patients with advanced gastric cancer or gastroesophageal junction (GEJ) cancer by 37% compared with patients using placebo. The median overall survival rate (OS) was 5.32 months, compared with 4.14 months in the placebo group.

In September 2017, the FDA approved Pembrolizumab for the treatment of PD-L1-positive advanced patients who had received second-line or more treatment of gastric cancer, including fluopyridine and platinum, and if applicable, HER-2 / neu targeted therapy .

However, exploring immune checkpoint inhibitors remains a challenge. In the phase III keynote-061 trial, Pembrolizumab did not improve the survival rate of patients with advanced gastric cancer (or GEJ) in second-line treatment. PD-1 inhibitors also failed to demonstrate a significant improvement in progression-free survival (PFS). The response rate of all patients was 10%, and the 1-year survival rate was approximately 25%, which was similar to the phase III results of nivolumab. However, these patients have undergone PD-L1 genetic testing, and the response rate of PD-L1 positive patients is 15%, while the negative rate is only 5%.

Pembrolizumab is approved for microsatellite unstable (MSI-H) tumors. In colon cancer, anti-PD-1 drugs are very active in msi-h tumors, with a response rate of 30% or 50%. In addition, valuable data have also been obtained in other msi-h tumors, with ≥50% of patients responding. Even in a large phase II extended clinical trial, 7 patients with MSI-H responded to 4 of them. Pembrolizumab has now been approved for PD-L1 positive MSI-H tumors and chemotherapy-resistant gastric cancer (or GEJ).

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

PiggyBac Transposon System
AI & Technology

PiggyBac Transposon System: A Revolutionary Tool in Cancer Gene Therapy

The PiggyBac Transposon System is revolutionizing genetic engineering in cancer research, especially in CAR T-cell therapy. With its high integration efficiency and large cargo capacity, it provides a powerful, non-viral alternative to traditional gene delivery methods. Learn how PiggyBac is advancing personalized cancer treatment and shaping the future of oncology.

Breakthrough 2025 Treatments for Advanced Breast Cancer
Biotech Innovations

Breakthrough Treatments for Advanced Breast Cancer in 2025

In 2025, advanced breast cancer treatment has entered a new era. Precision medicine and targeted therapies are enabling doctors to tailor care based on genetic profiles. Immunotherapy and antibody-drug conjugates are delivering more effective tumor targeting, while experimental cellular treatments like CAR T-cell therapy show immense promise. These cutting-edge options are transforming outcomes and quality of life for patients facing metastatic breast cancer. Explore the latest innovations driving hope and progress.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

We Are Online! Chat With Us!
Scan the code